VV116, mindeudesivir, deuremidevir for COVID-19

VV116, mindeudesivir, deuremidevir has been reported as potentially beneficial for treatment of COVID-19. We have not reviewed these studies. See all other treatments.

VV116, mindeudesivir, deuremidevir Submit Updates

Cao et al., VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2208822

McCarthy, M., VV116 as a potential treatment for COVID-19, Expert Opinion on Pharmacotherapy, doi:10.1080/14656566.2023.2193668

Choi et al., Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval, Journal of Korean Medical Science, doi:10.3346/jkms.2024.39.e134

Cao et al., Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116), Frontiers of Medicine, doi:10.1007/s11684-023-1037-3

Sha et al., Current state-of-the-art and potential future therapeutic drugs against COVID-19, Frontiers in Cell and Developmental Biology, doi:10.3389/fcell.2023.1238027

The novel coronavirus disease (COVID-19) continues to endanger human health, and its therapeutic drugs are under intensive research and development. Identifying the efficacy and toxicity of drugs in animal models is helpful for further screening of effective medications, which is also a prerequisite for drugs to enter clinical trials. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) invades host cells mainly by the S protein on its surface. After the SARS-CoV-2 RNA genome is injected into the cells, M protein will help assemble and release new viruses. RdRp is crucial for virus replication, assembly, and release of new virus particles. This review analyzes and discusses 26 anti-SARS-CoV-2 drugs based on their mechanism of action, effectiveness and safety in different animal models. We propose five drugs to be the most promising to enter the next stage of clinical trial research, thus providing a reference for future drug development.

Yang et al., Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115503

Xue et al., Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2, MedComm, doi:10.1002/mco2.254

Bekheit et al., Potential RNA-dependent RNA polymerase inhibitors as prospective drug candidates for SARS-CoV-2, European Journal of Medicinal Chemistry, doi:10.1016/j.ejmech.2023.115292

Xu et al., An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges, Biochemical Pharmacology, doi:10.1016/j.bcp.2022.115279

https://www.trialsitenews.com/p/trialsitenews/novel-chinese-oral-covid-19-treatment-begins..

https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0524/2022052301170.pdf

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0